 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Alnylam Steps Back from Huntington's Drug Deal, Sees Two Partnerships by Year-End
May 10, 2012
Alnylam Steps Back from Huntington's Drug Deal, Sees Two Partnerships by Year-End
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam Presents Clinical Data from Cholesterol Drug Trial, Animal Data from Huntington's Program
January 5, 2012 / Gene Silencing News - Alnylam, Medtronic to Get Funding for Huntington's Disease Program
November 4, 2010 / Gene Silencing News - Alnylam Forms Alliance with Genzyme in ATTR, Adds Another Notch to Partnership Belt
October 25, 2012 / Gene Silencing News - Alnylam Focuses on Two Lead Programs, Won't Advance Others without Partners
January 12, 2012 / Gene Silencing News - Tekmira Says Pipeline on Track Heading into Q4; Holds Course on Alnylam Litigation
November 10, 2011 / Gene Silencing News